
ALT A diagram with four quadrants categorizing risk factors based on baseline bleeding and wound-complication risk (y-axis) and baseline VTE risk (x-axis). - Top left: "Standard VTE risk, high bleeding risk," suggesting "Favors Aspirin." - Top right: "High VTE risk, high bleeding risk," advising "Individualize." - Bottom left: "Standard VTE risk, standard bleeding risk," indicating "Aspirin May Be Appropriate." - Bottom right: "High VTE risk, standard bleeding risk," recommending "Favors Anticoagulation." Axes labeled with thresholds as uncertain.
UK's first rooftop critical care garden opens in London - News

ALT Three graphs showing event-free survival (the primary end point) in the intention-to-treat analysis among patients in the intervention group (who received ponatinib plus blinatumomab) and in the control group (who received imatinib plus chemotherapy) (Panel A), along with molecular event-free survival (which was defined as an absence of measurable residual disease) (Panel B), and overall survival (Panel C).





































